We suspect that non-proliferation class HCC presents a higher incidence of CTNNB1 mutation [1, 40, 41], which promotes activation of the WNT/β-catenin pathway, resulting in immune evasion and resistance to anti–PD-1 immunotherapy [42]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.